Allogene Therapeutics ALLO Net Income
Net Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's net income?
- Allogene Therapeutics (ALLO) reported net income of -$42.61M in Q1 2026.
- How has Allogene Therapeutics's net income changed year-over-year?
- Allogene Therapeutics's net income increased by 28.7% year-over-year, from -$59.73M to -$42.61M.
- What is the long-term trend for Allogene Therapeutics's net income?
- Over 4 years (2021 to 2025), Allogene Therapeutics's net income has grown at a 1.2% compound annual growth rate (CAGR), from -$182.14M to -$190.89M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.